SEC Form 8-K: Press Release dated July 8, 2024

BPTH_8-K_07112024

Bio-Path Holdings Provides Clinical Update and Expansion Plans

BPTH_-Provides_Clinical_Update_and_Expansion_Plans

SEC Form 8-K: Press Release dated June 14, 2024

BPTH_Form_8-K_06-14-24_Press_Release

SEC Form 424b3 Prospectus – June 14, 2024

BPTH_Prospectus_Resale_June_2024_PIPEDownload

SEC Form 8-K: re Nasdaq Extension

BPTH_Form_8-K_Nasdaq-Extension

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

BPTH_EHA_Data_Press_Release

SEC Form S-3

BPTH_Form_S-3_Resale_Registration_Statement_20240611_PIPE

SEC Form 8-K: Press Release dated June 5, 2024

BPTH_8-K_20240605

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH_PIPE_PR_20240605

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH_PR_June_2024_PIPE